Spero Therapeutics (SPRO) Return on Sales (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Return on Sales came in at 0.09% in Q1 2026, up 1147.0% YoY from 0.01% in Q1 2025, and down 487.0% on a QoQ basis from 0.02% in Q4 2025.
Spero Therapeutics (SPRO) Return on Sales (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Return on Sales data on file, last reported at 0.09% in Q1 2026.
- Quarterly Return on Sales rose 1147.0% year-over-year to 0.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.09% (up 9.0% YoY) and the FY2025 annual result came in at 0.0%, up 515.0% from the prior year.
- Return on Sales eased to 0.09% in Q1 2026, from 0.02% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.02% in Q4 2025 to a low of 45.61% in Q3 2025.
- A 5-year average of 6.61% and a median of 0.29% in 2022 frame the typical range for Return on Sales.
- The widest YoY moves for Return on Sales: up 2746 bps in 2025, down 4307 bps in 2025.
- Tracing SPRO's Return on Sales over 5 years: stood at 0.06% in 2022, then surged by 137 bps to 0.02% in 2023, then plunged by 135170 bps to 27.44% in 2024, then soared by 100 bps to 0.02% in 2025, then tumbled by 487 bps to 0.09% in 2026.
- The last three Return on Sales figures came in at 0.09% (Q1 2026), 0.02% (Q4 2025), and 45.61% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 0.00% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 0.00% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.00% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 0.00% |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.02% |
| Mar 31, 2026 | -0.09% |
| Dec 31, 2025 | 0.02% |
| Sep 30, 2025 | -45.61% |
| Jun 30, 2025 | -21.76% |
| Mar 31, 2025 | -11.56% |
| Dec 31, 2024 | -27.44% |
| Sep 30, 2024 | -2.55% |
| Jun 30, 2024 | -0.02% |
| Mar 31, 2024 | -0.90% |
| Dec 31, 2023 | 0.02% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | -0.04% |
| Mar 31, 2023 | -0.59% |
| Dec 31, 2022 | -0.06% |
| Sep 30, 2022 | -0.11% |
| Jun 30, 2022 | -0.29% |
| Mar 31, 2022 | -1.38% |
| Dec 31, 2021 | 0.10% |
| Sep 30, 2021 | -0.79% |